Top Ten Lessons Learned from Trials in Oligometastatic Cancers

被引：8
|
作者：
Tan, Vivian S. [1 ]
Palma, David A. [1 ,2 ]
机构：
[1] Univ Western Ontario, Dept Radiat Oncol, London, ON, Canada
[2] London Hlth Sci Ctr, STN B, 800 Commissioners Rd E POB 5010, London, ON 6A 5W9, Canada
来源：
CANCER RESEARCH AND TREATMENT | 2023年 / 55卷 / 01期
关键词：
Oligometastatic; Stereotactic; Metastases; Stereotactic ablative radiotherapy; Stereotactic body radiation therapy; LOCAL CONSOLIDATIVE THERAPY; METASTASIS-DIRECTED THERAPY; PHASE-II; SINGLE-ARM; RADIOTHERAPY; MULTICENTER; ONCOLOGY; DISEASE; SABR;
D O I：
10.4143/crt.2022.1460
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recent evidence supports the role of aggressive local treatment in the oligometastatic setting. In this review, we discuss the top 10 lessons we have learned from trials in oligometastatic cancers. Major lessons learned pertain to definitions of oligometastatic dis-ease, outcomes, toxicity, costs, and the combination of ablative therapies with systemic therapy, including immunotherapy. Barriers to accrual for trials and upcoming phase III trials are also reviewed. These lessons may help to inform clinical practice and may be the basis for future research in the oligometastatic space.
引用
收藏
页码：5 / 14
页数：10
相关论文
共 50 条
12345